Market Access Lessons For Cell And Gene Therapies In Germany
Companies Can Learn From Bluebird Bio’s Failed Zynteglo Pricing Deal
Lawyer and industry expert Alexander Natz sets out some important dos and don’ts for securing a successful launch of an advanced therapy in Germany.
You may also be interested in...
No evidence has been found linking the viral vector in bluebird’s gene therapy for β-thalassemia to blood cancer, the European Medicines Agency says.
If approved, new legislation would allow hospitals to apply for funding for ATMPs before marketing authorization.
The EU is set to be the first market to approve bluebird bio’s one-time gene therapy for cerebral adrenoleukodystrophy.